title: cis-Hydroxyproline-mediated pancreatic carcinoma growth inhibition in mice.
abstract: OBJECTIVE
  This study addressed the question of whether the collagen metabolism modulator cis-4-Hydroxy-L-proline (CHP) is applicable for potential use as a therapeutic inhibitor of pancreatic carcinoma cell growth.
  
  
  METHODS
  Cell proliferation, as well as quantification of apoptosis of murine Panc02 cells, was assessed after CHP treatment. Supplementary, the effect of CHP on tumor growth was examined in the subcutaneous Panc02 model in vivo. Mice received daily intraperitoneal injections of CHP (300, 400, and 500 mg/kg bw). In addition to the assessment of systemic parameters (blood count, enzyme activities), histology (HE) and immunohistochemistry (Ki-67) were performed from resected tumor specimens.
  
  
  RESULTS
  Like reduction of metabolic activity, CHP also induced inhibition of cell growth in a dose-dependent manner, with however only slight increases in apoptosis. In vivo treatment of Panc02 tumors with CHP resulted in pronounced delay of tumor growth and decreases in tumor cell proliferation. Moreover, these effects were accompanied by a massive systemic leukocytosis as well increased leukocyte infiltration into the tumors subsequent to CHP therapy.
  
  
  CONCLUSIONS
  CHP inhibits the proliferation of Panc02 tumor cells in a dose-dependent manner both in vitro and in vivo. Our presented data show that modulation of the collagen metabolism is an interesting strategy for treatment of pancreatic carcinoma.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, University of Rostock, Rostock, Germany.
authors.forename: Dietrich
authors.initials: D
authors.lastname: Sturm
authors.forename: Claudia
authors.initials: C
authors.lastname: Maletzki
authors.forename: Dagmar
authors.initials: D
authors.lastname: Braun
authors.forename: Joerg
authors.initials: J
authors.lastname: Emmrich
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001973:Bromodeoxyuridine / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D003094:Collagen / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D005434:Flow Cytometry; D006909:Hydroxyproline / Q000494:pharmacology* / Q000627:therapeutic use*; D007700:Kinetics; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*
chemical_list: D003094:Collagen; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001973:Bromodeoxyuridine; D006909:Hydroxyproline
references.citation: Drugs. 2007;67(16):2293-310
references.pmid: 17983252
references.citation: Best Pract Res Clin Gastroenterol. 2008;22(1):17-29
references.pmid: 18206810
references.citation: Anticancer Drugs. 2008 Jun;19(5):435-46
references.pmid: 18418211
references.citation: J Biol Chem. 1971 Mar 25;246(6):1549-55
references.pmid: 5547696
references.citation: Cancer Res. 1988 May 1;48(9):2483-91
references.pmid: 2833347
references.citation: Gut. 2008 Apr;57(4):483-91
references.pmid: 18025068
references.citation: In Vivo. 2000 Jan-Feb;14(1):7-11
references.pmid: 10757055
references.citation: Cancer Chemother Pharmacol. 2008 Nov;62(6):1111-2
references.pmid: 18283460
references.citation: Cancer Res. 1984 Feb;44(2):717-26
references.pmid: 6692374
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4787-92
references.pmid: 17947726
references.citation: Mol Cancer Ther. 2006 May;5(5):1108-16
references.pmid: 16731742
references.citation: World J Gastroenterol. 2006 Mar 14;12(10):1569-76
references.pmid: 16570349
references.citation: Cancer Chemother Pharmacol. 1992;29(6):485-9
references.pmid: 1348974
references.citation: Invest Ophthalmol Vis Sci. 1997 Feb;38(2):520-8
references.pmid: 9040485
references.citation: Anticancer Res. 2008 Mar-Apr;28(2B):1303-8
references.pmid: 18505070
references.citation: Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):412-22
references.pmid: 19506583
references.citation: Cancer Treat Rev. 2009 Jun;35(4):335-9
references.pmid: 19131170
references.citation: Pancreas. 2008 Mar;36(2):146-52
references.pmid: 18376305
references.citation: Mol Cancer Ther. 2007 Apr;6(4):1186-97
references.pmid: 17406031
references.citation: Hepatogastroenterology. 2009 May-Jun;56(91-92):861-5
references.pmid: 19621718